



**HAL**  
open science

## Preoperative cytological and histological diagnosis of breast lesions: a critical review

B. Kooistra, C. Wauters, L. Strobbe, T. Wobbes

### ► To cite this version:

B. Kooistra, C. Wauters, L. Strobbe, T. Wobbes. Preoperative cytological and histological diagnosis of breast lesions: a critical review. *EJSO - European Journal of Surgical Oncology*, 2010, 36 (10), pp.934. <10.1016/j.ejso.2010.06.014>. <hal-00625567>

**HAL Id: hal-00625567**

**<https://hal.science/hal-00625567v1>**

Submitted on 22 Sep 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.




HAL Authorization

# Accepted Manuscript

Title: Preoperative cytological and histological diagnosis of breast lesions: a critical review

Authors: B. Kooistra, MScC. Wauters, MDL. Strobbe, MD, PhDT. Wobbes, MD, PhD



PII: S0748-7983(10)00190-3

DOI: [10.1016/j.ejsso.2010.06.014](https://doi.org/10.1016/j.ejsso.2010.06.014)

Reference: YEJSO 3002

To appear in: *European Journal of Surgical Oncology*

Received Date: 26 February 2010

Revised Date: 20 May 2010

Accepted Date: 7 June 2010

Please cite this article as: Kooistra B, Wauters C, Strobbe L, Wobbes T. Preoperative cytological and histological diagnosis of breast lesions: a critical review, *European Journal of Surgical Oncology* (2010), doi: 10.1016/j.ejsso.2010.06.014

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Preoperative cytological and histological diagnosis of breast lesions: a critical review

B. Kooistra, MSc<sup>a</sup>, C. Wauters, MD<sup>b</sup>, L. Strobbe, MD, PhD<sup>a</sup>,  
and T. Wobbes, MD, PhD<sup>c</sup>

<sup>a</sup>*Department of Surgery, Canisius Wilhelmina Ziekenhuis, Weg door Jonkerbosch 100, 6532 SZ  
Nijmegen, The Netherlands*

<sup>b</sup>*Department of Pathology, Canisius Wilhelmina Ziekenhuis, Weg door Jonkerbosch 100, 6532 SZ  
Nijmegen, The Netherlands*

<sup>c</sup>*Department of Surgery, Radboud University Medical Centre Nijmegen, Postbus 9101, 6500  
HB Nijmegen, The Netherlands*

### Article type

Review Article

### Corresponding author

Bauke Kooistra  
Weg door Jonkerbos 100  
6532 SZ Nijmegen  
The Netherlands  
Telephone: 0031-243658510  
Fax: 0031-243658844  
Email: baukekooistra@hotmail.com

### Email addresses of co-authors

CW: c.wauters@cwz.nl  
LS: ljastrobbe@cwz.nl  
TW: t.wobbes@chir.umcn.nl

### Statement of expertise

The first author, BK, has recently published several papers on fine needle aspiration, core needle biopsy and nipple discharge cytology.

CW is an experienced pathologist and cytopathologist with special scientific interest in the position the diagnostic pathology in preoperative work-up of breast lesions.

LS is a breast surgeon with special interest in preoperative work-up and has supervised several research projects on this subject in the past years.

The senior author, TW, is an experienced professor in surgical oncology with special interest in diagnosis and surgical treatment of breast pathology.

### Key words

Breast pathology; fine needle aspiration; core needle biopsy; core wash cytology; touch imprint cytology; breast surgery.

## ABSTRACT

### Background

Non-operative pathology diagnoses constitute an essential part of the work-up of breast lesions. With fine needle aspiration (FNA) and core needle biopsy (CNB) both having unique advantages, there is an increasing acceptance of CNB. This paper aims to outline the scientific basis of this trend.

Additionally, we provide an update on novel techniques that derive cytological specimens from CNB (i.e., touch imprint (TI) and core wash (CW) cytology) in an attempt to get the best of both worlds.

### Methods

In addition to using the authors' experience, we performed a search of the Medline database combining the search terms “breast cancer diagnosis”, “core needle biopsy”, “fine needle aspiration”, “touch imprint cytology”, “core wash cytology” and “complications”.

We defined a conclusive non-operative diagnosis as “malignant” in lesions that were malignant on follow-up and “benign” in lesions that were benign on follow-up.

### Results

CNB was more often conclusive than FNA in benign and malignant lesions in 4 prospective studies. Although the more rapid diagnoses by FNA result in less patient anxiety during diagnostic work-up, CNB allows for fairly reliable estimation of invasion, histological type, grade, and receptor expression. CW and TI cytology seem promising techniques with conclusiveness rates that are roughly comparable to that of FNA.

### Conclusions

All new suspicious breast lesions require careful non-operative investigation by CNB. However, additional cytological assessment by FNA can still be useful as a same-day diagnosis decreases patient anxiety and facilitates surgical treatment planning. TI and CW cytology techniques are promising same-day diagnosis modalities.

## INTRODUCTION

Present-day non-operative diagnosis of palpable breast lesions comprises ‘triple assessment’ by physical examination, imaging (mammography and/or ultrasound (US)), and pathology (fine needle aspiration (FNA) or core needle biopsy (CNB)).[1,2] This diagnostic work-up precludes standard excisional biopsy when all three components of the triple assessment are conclusively positive (~100% probability of malignancy) or conclusively negative (~100% probability of a benign lesion).[3-5]

Cytological and histological specimens are conventionally diagnosed as “inadequate”, “benign”, “atypical”, “suspicious”, or “malignant” (**Table 1**). The diagnostic value of a needle biopsy depends on whether it yields a decisive and accurate diagnosis. This is what we define as a *conclusive* diagnosis in this paper. Specifically, a conclusive diagnosis by FNA or CNB is defined as a ‘benign’ diagnosis (C2/B2) in a truly benign lesion and a ‘malignant’ diagnosis (C5/B5) in truly malignant lesions. Consequently, we will refer to diagnostic ‘conclusiveness’ as the proportion of “benign” (C2/B2) diagnoses in benign lesions and as the proportion of “malignant” (C5/B5) diagnoses in malignant lesions.[6]

Due to the introduction of nationwide mammographic screening programmes, however, the proportion of small, nonpalpable breast lesions presenting as microcalcifications on mammography has risen.[7,8] Additionally, the increasing use of magnetic resonance imaging (MRI) screening in high-risk women has further increased the number of small tumours in which malignancy can only be excluded or confirmed conclusively by MRI-guided percutaneous needle biopsy.[9] As such, the role of a pathology diagnosis in stratifying patients to surgery or clinical follow-up has increased and surgeons’ confidence in such decisions depends upon the conclusiveness of non-operative pathology diagnoses.[10]

While FNA is a traditional modality that has been used as a rapid and safe tool for distinguishing benign from malignant breast lesions,[11] CNB has been increasingly employed since the 1980’s. Its main advantage is that it provides preoperative knowledge of a histological diagnosis and prognostic factors.[12] Vacuum assisted biopsy (VAB) systems are recent large-core variants of CNB.

With cytology and CNB both having unique advantages, there is an increasing acceptance of CNB for evaluating breast lesions.[10,13] This paper aims to outline the scientific basis of this trend, focussing on diagnostic accuracy, impact on surgical management, prognosis assessment and complications of these modalities. Finally, we will discuss needle biopsy techniques that combine cytology and histology.

## **DIAGNOSTIC ACCURACY**

### *Comparative accuracies*

The histological sample collected by the large-calibre, 7-18 Gauge needles used for CNB allow for a tissue diagnosis and could rationally be expected to yield more representative and more readily interpretable material than the smaller 20-25 Gauge FNA needles that only allow for cytological examination. Many authors have claimed CNB to have superior diagnostic accuracy based on solely historical comparisons of CNB and FNA series.[14-16]

In fact, few studies have directly compared FNA and CNB regarding their diagnostic accuracies that is, they prospectively investigated the same patients with both modalities (**Figure 1**).[17-23] In these studies CNB has repeatedly, but not invariably, been shown to yield more conclusive diagnoses than FNA in both malignant and benign lesions. This implies that CNB is imperative to the treatment planning of all breast lesions.

However, this does not exclude FNA from the preoperative pathology work-up. In fact, combining both modalities may result in an even higher conclusiveness. Specifically, using FNA in conjunction with CNB may increase conclusiveness rates with 5%-16% in malignant lesions and with 0%-2% in benign lesions.[19,21,23] As such, the role of FNA as complementary to CNB, facilitating definitive exclusion or confirmation of malignancy in case of an indeterminate CNB, has been suggested.[17] Yet, indeterminate primary FNA invariably mandate a CNB.[24]

### *Factors affecting conclusiveness*

Generally, diagnostic modalities that yield consistently conclusive results irrespective of the operator and interpreter involved are most useful to breast pathology patients. Specimen adequacy is considered

to be less operator-dependent for CNB than for FNA,[25] but operator experience has been identified to impact CNB success and no study has compared this in relation to FNA.[26,27] As for microscopic assessment, CNB has been shown to produce highly reliable results in a study of more than 2400 biopsies, with a chance-corrected interobserver agreement ( $\kappa$ ) of 0.90.[28] In contrast, FNA conclusiveness varies significantly among pathologists, but is not affected by the amount of experience in cytopathology.[29] Currently however, it cannot be estimated which modality yields the most consistent results as no directly comparative studies exist.

Irrespective of these flexible parameters, relatively simple clinical and radiologic lesion characteristics can serve to predict whether an FNA or CNB will be informative. For FNA, small (<1 cm) and large (>4 cm) tumours, freehand aspiration and lesions appearing as microcalcifications on mammogram have been associated with inconclusive diagnoses.[30-33] In contrast, CNB, especially VAB which samples a greater tissue volume, exhibits comparable conclusiveness rates in microcalcifications and masses.[27,34]

Even after aspiration, FNA conclusiveness can be increased by having an on-site cytopathologist assessing specimen adequacy[35] and by processing the aspirate to create a monolayer preparation (versus directly smearing it) in the laboratory.[36]

## IMPACT ON SURGICAL MANAGEMENT

Obviously, conclusively benign FNA or CNB diagnoses obviate the need for excisional biopsy, provided that imaging and examination are concordantly benign,[4,37,38] and reducing redundant surgeries is in fact one of the major goals in breast care.[39] Similarly, conclusive FNA or CNB decrease the number of surgical procedures in malignant lesions.[37,40] Accordingly, both FNA and CNB are cost-effective modalities.[41,42]

Yet, important differences between FNA and CNB exist (**Table 2**). FNA allows for a rapid diagnosis within 30 minutes, providing immediate reassurance to the majority of patients with benign disease and minimizing the psychologically stressful period of waiting for a malignant diagnosis.[43,44] In a 670-patient randomized controlled trial, patients attending a one-stop breast

clinic were less anxious on the short term than those randomized to delayed discussion of diagnostic results.[45] Additionally, direct conclusive diagnoses obviate further review appointments in patients with benign lesions and facilitate the surgical scheduling in breast cancer patients.[45] However, FNA cannot accurately assess histological information key to adequate surgical treatment planning for malignancies. Here lies the main advantage of CNB.

First, CNB can differentiate between ductal carcinoma in situ (DCIS) and invasive ductal carcinoma. This conveys important information since pure DCIS lesions often require larger tissue removal and only necessitate sentinel node biopsy in selected cases.[46-48] However, due to selective sampling, invasion is underestimated in 9%-38% of cases showing DCIS on CNB.[27,40,48-50] Consequently, these patients will require a second operative procedure for axillary staging. As for FNA, having similar sampling problems for DCIS, specimens lack sufficiently specific cytomorphological aspects to predict invasion or absence thereof.[51,52] Therefore, all patients with a malignant FNA diagnosis should have sentinel node biopsy to ensure adequate axillary staging for invasive cancers. However, the patients who ultimately prove to have pure DCIS will have an unnecessary sentinel node biopsy. As such, many centres prefer CNB to individualize the choice to perform axillary staging.

Second, CNB can better distinguish invasive lobular from invasive ductal carcinoma than FNA as the infiltrating pattern is characteristic on histology and epithelial markers can confirm the diagnosis.[53,54] Preoperative knowledge of specific tumour histology is fundamental to planning the extent of surgery since lobular carcinoma carries an increased risk of positive lumpectomy margins and synchronous contralateral disease.[55,56]

Nevertheless, the more specific nature of histological diagnoses provided by CNB also poses therapeutic dilemmas when B3, 'high-risk' lesions are found on CNB. These include atypical ductal hyperplasia (ADH), lobular carcinoma in situ (LCIS), atypical papillomatosis, flat epithelial atypia and radial scars/complex sclerosing lesions. As these lesions can mimic and, if diagnosed correctly, can be associated with malignancy,[57,58] possible underestimations of surrounding DCIS and invasive cancer should be kept in mind. As such, surgical excision is warranted in lesions with high underestimation risks, such as ADH.[58] Although the increasing use of large-bore VAB reduces the

risk of missing adjacent cancer by sampling more breast tissue, more patients with benign disease will accidentally be found to have borderline lesions and may have redundant excisions or follow-up.

### **ASSESSMENT OF PROGNOSTIC AND PREDICTIVE FACTORS BY PERCUTANEOUS NEEDLE BIOPSY**

The increasing use of neoadjuvant therapy has resulted in a more frequent need for knowledge of prognostic and predictive tumour characteristics.[59] These include histologic grade and subtype, estrogen receptor (ER), progesterone receptor (PR) and HER2-neu status, and are key to planning both neoadjuvant and adjuvant treatment when neoadjuvant therapy is considered. Additionally, the type of medical therapy is partly determined by receptor expressions in patients unfit for excision or in patients who present with metastatic disease. CNB is considered to provide reliable assessments of prognostic and predictive factors, exhibiting high concordance rates with surgical specimens for tumour grade (59%-91%), ER status (78%-100%), PR status (71%-91%) and HER2-neu status (60%-100%).(reviewed in[60])

There have been successful attempts to assess receptor expression on FNA specimens,[61,62] however, accurate assessment of histological grade is only possible on CNB. Yet, grade may still be underestimated by CNB due to regional differences in primary tumour differentiation,[63] Although cytological grading on FNA specimens has been shown to correlate with histologic grade,[64] its relation with histological grade on the surgical specimen, response to chemotherapy and prognosis is unknown. Also, as FNA cannot discriminate between DCIS and invasive carcinoma, the meaning of a given cytological grade for malignant FNA remains unknown.

### **COMPLICATIONS**

The main complication of both FNA and CNB is pain during the biopsy procedure. It seems obvious that larger needles would cause more biopsy-related pain, as measured by a validated visual analogue scale.[65] This has indeed been demonstrated in a randomized controlled trial on 104 patients comparing 23-gauge and 21-gauge FNA and in a prospective cohort study comparing 21-gauge FNA

and 14-gauge CNB.[66,67] Contrarily, in a recent prospective cohort study of 220 biopsies, patients undergoing 21-gauge FNA had significantly more pain than those having 14-gauge CNB or 11-gauge VAB.[68] However, this study did not adjust for patient-related factors that may influence pain perception, such as psychological distress.

By directing FNA and CNB needles towards the chest wall, pneumothorax may occasionally result, especially in the tail of the breast. However, larger series have reported pneumothorax rates of only 1 and 5 in 10 000 cases for FNA and CNB, respectively.[69,70]

Hematoma formation can be expected after any needle biopsy, but hematomas requiring intervention are uncommon, occurring in less than 1% of both FNAs and CNBs.[70-73] Similarly, needle tract infection is an infrequent complication, with reported rates of 0-2% and 0.01%-0.2% for FNA and CNB, respectively.[70,72-74]

Additionally, malignant cells may be displaced along the needle tract in up to 50% of breast cancers sampled by CNB, [75-77] while for FNA no recent data are available. However, it is unlikely that malignant cell seeding impacts recurrence and survival.[78,79]

### **COMBINING CYTOLOGY AND HISTOLOGY IN PREOPERATIVE WORK-UP**

In an attempt to combine the unique benefits of a same-day diagnosis, enhanced diagnostic accuracy and histological information in a single percutaneous needle biopsy, laboratory techniques that derive cytological specimens from CNBs have been investigated recently. Touch imprint (TI) cytology involves smearing the CNB specimen onto a microscopic slide prior to final formalin fixation. Alternatively, core wash (CW) cytology specimens are prepared by washing the tissue contained in the needle notch in a saline or cell-preserving solution. For CW, either a smear, involving air drying of the cell-containing solution, or a liquid-based preparation, using a cytocentrifuge, is then created.

Similar to FNA, the success of TI and CW cytology depends on the conclusiveness with which a preliminary diagnosis can be given to the patient. The results of studies focussing on the conclusiveness of these modalities are summarized in **Table 3**.

Studies on TI cytology have found conclusiveness rates ranging from 44-93% in benign lesions and from 42%-100% in malignant lesions.[80-89] Unfortunately, only 2 studies used the final

diagnosis by surgical or clinical follow-up as the gold standard.[85,87] Conversely, the other studies only correlated TI cytology diagnoses to the later CNB diagnoses (a surrogate gold standard assessment). As CNB can miss cancers and falsely diagnose non-malignant lesions as malignant (**Figure 1**), the true conclusiveness of TI cytology may have been under- or overestimated in these studies.

The use of CW cytology has been questioned due to conclusiveness rates in both benign and malignant lesions being lower than 40%.[90,91] In a prospective study of 236 benign and 210 malignant cases, Uematsu and Kasami found 42% of CW samples to be inadequate (C1). Therefore, they concluded that CW is not useful for same-day diagnosis of breast lesions.[91] Contrarily, in a small prospective laboratory study using a modified CW procedure on 30 breast lesions only 1 specimen was found to be inadequate.[85] This resulted in higher conclusiveness rates than those previously found.

The same study explored whether CW and TI cytology had different conclusiveness rates in the same patient population. Conclusiveness was demonstrated to be identical in malignant lesions (both 75%), but slightly higher for CW cytology in benign lesions (89% vs. 67%, respectively,  $P=.26$ ).[85] Yet, the true comparative conclusiveness rates are currently unknown as larger studies are lacking.

From the results of the above studies, it is apparent that TI and CW cytology are promising relatively new techniques that frequently enable a same-day diagnosis of benign or malignant breast lesions.

## CONCLUSIONS

All new suspicious breast lesions require careful non-operative investigation by CNB. This is mainly because of its superior diagnostic accuracy, its potential to distinguish in situ from invasive carcinoma and its ability to assess prognostic and predictive tumour characteristics. However, additional cytological assessment by FNA can still be useful as a same-day diagnosis decreases patient anxiety and facilitates surgical treatment planning. TI and CW cytology techniques seem accurate alternative same-day diagnosis modalities.

**CONFLICT OF INTEREST STATEMENT**

We had no relationship with other persons or organisations, both financial and personal that could potentially bias the present work.

**ROLE OF THE FUNDING SOURCE**

We did not receive any funding for creating this paper or any related activity.

**REFERENCES**

1. Holloway CM, Saskin R, Brackstone M, Paszat L. Variation in the use of percutaneous biopsy for diagnosis of breast abnormalities in Ontario. *Ann Surg Oncol* 2007;14:2932-9.
2. Association of Breast Surgery at Baso 2009. Surgical guidelines for the management of breast cancer. *Eur J Surg Oncol* 2009;35 Suppl1:1-22.
3. Morris A, Pommier RF, Schmidt WA, Shih RL, Alexander PW, Vetto JT. Accurate evaluation of palpable breast masses by the triple test score. *Arch Surg* 1998;133:930-4.
4. Morris KT, Stevens JS, Pommier RF, Fletcher WS, Vetto JT. Usefulness of the triple test score for palpable breast masses. *Arch Surg* 2001;136:1008-12.
5. Eltahir A, Jibril JA, Squair J, et al. The accuracy of "one-stop" diagnosis for 1,110 patients presenting to a symptomatic breast clinic. *J R Coll Surg Edinb* 1999;44:226-30.
6. Wells CA, Ellis IO, Zakhour HD, Wilson AR. Guidelines for cytology procedures and reporting on fine needle aspirates of the breast. *Cytopathology* 1994;5:316 –34.
7. Fracheboud J, de Koning HJ, Boer R, et al. Nationwide breast cancer screening programme fully implemented in the Netherlands. *Breast* 2001;10:6-11.
8. Katalinic A, Bartel C, Raspe H, Schreer I. Beyond mammography screening. quality assurance in breast cancer diagnosis (The QuaMaDi Project). *Br J Cancer* 2007;96:157-61.

9. Landheer MLEA, Veltman J, Eekeren R van, Zeillemaker AM, Boetes C, Wobbes T. MRI-guided preoperative wire localization of nonpalpable breast lesions. *Clin Imaging* 2006;30:229-33.
10. Holloway CM, Gagliardi AR. Percutaneous needle biopsy for breast diagnosis: how do surgeons decide? *Ann Surg Oncol* 2009;16:1629-36.
11. Martin HE, Ellis EB. Biopsy by needle puncture and aspiration. *Ann Surg* 1930;92:169-181.
12. Foster RS Jr. Core-cutting needle biopsy for the diagnosis of breast cancer. *Am J Surg* 1982;143:622-3.
13. Tabbara SO, Frost AR, Stoler MH, Sneige N, Sidawy MK. Changing trends in breast fine-needle aspiration: results of the Papanicolaou Society of Cytopathology Survey. *Diagn Cytopathol* 2000;22:126-30.
14. El-Sayed ME, Rakha EA, Reed J, Lee AH, Evans AJ, Ellis IO. Audit of performance of needle core biopsy diagnoses of screen detected lesions. *Eur J Cancer* 2008;44:2580-6.
15. Shannon J, Douglas-Jones AG, Dallimore NS. Conversion to core biopsy in preoperative diagnosis of breast lesions: is it justified by results? *J Clin Pathol* 2001;54:762-5.
16. Pijnappel RM, van den Donk M, Holland R, et al. Diagnostic accuracy for different strategies of image-guided breast intervention in cases of nonpalpable breast lesions. *Br J Cancer* 2004;90:595-600.
17. Dennison G, Anand R, Makar SH, Pain JA. A prospective study of the use of fine-needle aspiration cytology and core biopsy in the diagnosis of breast cancer. *Breast J* 2003;9:491-3.
18. Ballo MS, Sneige N. Can core needle biopsy replace fine-needle aspiration cytology in the diagnosis of palpable breast carcinoma: A comparative study of 124 women. *Cancer* 1996;78:773-7.
19. Westenend PJ, Sever AR, Beekman-De Volder HJ, Liem SJ. A comparison of aspiration cytology and core needle biopsy in the evaluation of breast lesions. *Cancer (Cancer Cytopathol)* 2001;93:146-50.
20. Clarke D, Sudhakaran N, Gateley CA. Replace fine needle aspiration cytology with automated core biopsy in the triple assessment of breast cancer. *Ann R Coll Surg Engl* 2001;83:110-2.

21. Garg S, Mohan H, Bal A, Attri AK, Kochhar S. A comparative analysis of core needle biopsy and fine-needle aspiration cytology in the evaluation of palpable and mammographically detected suspicious breast lesions. *Diagn Cytopathol* 2007;35:681-9.
22. Symmans WF, Weg N, Gross J, et al. A prospective comparison of stereotaxic fine-needle aspiration versus stereotaxic core needle biopsy for the diagnosis of mammographic abnormalities. *Cancer* 1999;85:1119-32.
23. Barra Ade A, Gobbi H, de L Rezende CA, et al. A comparison of aspiration cytology and core needle biopsy according to tumor size of suspicious breast lesions. *Diagn Cytopathol* 2008;36:26-31.
24. Kooistra B, Wauters C, Strobbe L. Indeterminate breast fine-needle aspiration: repeat aspiration or core needle biopsy? *Ann Surg Oncol* 2009;16:281-4.
25. Rotten D, Levallant JM, Leridon H, Letessier A, Sandres M. Ultrasonographically guided fine needle aspiration cytology and core-needle biopsy in the diagnosis of breast tumors. *Eur J Obstet Gynecol Reprod Biol* 1993;49:175-86.
26. Brenner RJ, Fajardo L, Fisher PR, et al. Percutaneous core biopsy of the breast: effect of operator experience and number of samples on diagnostic accuracy. *AJR Am J Roentgenol* 1996;166:341-6.
27. Ciatto S, Houssami N, Ambrogetti D, et al. Accuracy and underestimation of malignancy of breast core needle biopsy: the Florence experience of over 4000 consecutive biopsies. *Breast Cancer Res Treat* 2007;101:291-7.
28. Collins LC, Connolly JL, Page DL, et al. Diagnostic agreement in the evaluation of image-guided breast core needle biopsies: results from a randomized clinical trial. *Am J Surg Pathol* 2004;28:126-31.
29. Gornstein B, Jacobs T, Bédard Y, et al. Interobserver agreement of a probabilistic approach to reporting breast fine-needle aspirations on ThinPrep. *Diagn Cytopathol* 2004;30:389-95.
30. Houssami N, Ciatto S, Ambrogetti D, et al. Florence-Sydney Breast Biopsy Study: sensitivity of ultrasound-guided versus freehand fine needle biopsy of palpable breast cancer. *Breast Cancer Res Treat* 2005;89:55-9.

31. Barrows GH, Anderson T, Lamb JL, Dixon JM. Fine-needle aspiration of breast cancer. Relationship of clinical factors to cytology results in 689 primary malignancies. *Cancer* 1986;58:1493-8.
32. Pisano ED, Fajardo LL, Tsimikas J, et al. Rate of insufficient samples for fine-needle aspiration for nonpalpable breast lesions in a multicentre clinical trial. The radiologic diagnostic oncology group 5 study. *Cancer* 1998;82:679-88.
33. Manfrin E, Falsirollo F, Remo A, et al. Cancer size, histotype, and cellular grade may limit the success of fine-needle aspiration cytology for screen-detected breast carcinoma. *Cancer Cytopathol* 2009; 117:491-9.
34. Jackman RJ, Marzoni FA Jr, Rosenberg J. False-negative diagnoses at stereotactic vacuum-assisted needle breast biopsy: long-term follow-up of 1,280 lesions and review of the literature. *AJR Am J Roentgenol* 2009;192:341-51.
35. Nasuti JF, Gupta PK, Baloch ZW. Diagnostic value and cost-effectiveness of on-site evaluation of fine-needle aspiration specimens: review of 5,688 cases. *Diagn Cytopathol* 2002;27:1-4.
36. Wauters C, Kooistra B, Strobbe LJA. The role of laboratory processing in determining diagnostic conclusiveness of breast fine needle aspirations: conventional smearing versus a monolayer preparation. *J Clin Pathol* 2009;62:931-4.
37. Rubin M, Horiuchi K, Joy N, et al. Use of fine needle aspiration for solid breast lesions is accurate and cost-effective. *Am J Surg* 1997;174:694-696.
38. Green B, Dowley A, Turnbull LS, Smith PA, Leinster SJ, Sinstanley JH. Impact of fine-needle cytology, ultra-sonography and mammography on open biopsy rate in patients with benign breast disease. *Br J Surg* 1995;82:1509-11.
39. Silverstein MJ, Recht A, Lagios MD, et al. Special report: Consensus conference III. Image-detected breast cancer: state-of-the-art diagnosis and treatment. *J Am Coll Surg* 2009;209:504-

40. White RR, Halperin TJ, Olson JA Jr, Soo MS, Bentley RC, Seigler HF. Impact of core-needle breast biopsy on the surgical management of mammographic abnormalities. *Ann Surg* 2001;233:769–77.
41. Buijs-van der Woude T, Verkooijen HM, Pijnappel RM, et al; COBRA study group. Cost comparison between stereotactic large-core-needle biopsy versus surgical excision biopsy in The Netherlands. *Eur J Cancer* 2001;37:1736-45.
42. Logan-Young W, Dawson AE, Wilbur DC, et al. The cost-effectiveness of fine-needle aspiration cytology and 14-gauge core needle biopsy compared with open surgical biopsy in the diagnosis of breast carcinoma. *Cancer* 1998;82:1867-73.
43. Ubhi SS, Shaw P, Wright S et al. Anxiety in patients with symptomatic breast disease: effects of immediate versus delayed communication of results. *Ann R Coll Surg Engl* 1996;78:466-9.
44. Henselmans I, Sanderman R, Smink A, Ranchor AV, de Vries J. The sooner, the better? Psychological consequences of waiting in breast disease clinics. *Ned Tijdschr Geneeskd* 2010;154: B491 [article in Dutch].
45. Dey P, Bundred N, Gibbs A, et al. Costs and benefits of a one stop clinic compared with a dedicated breast clinic: randomised controlled trial. *BMJ* 2002;324:507.
46. Intra M, Rotmensz N, Veronesi P, et al. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European institute of oncology on 854 patients in 10 years. *Ann Surg* 2008;247:315-9.
47. Masood S. Core needle biopsy versus fine needle aspiration biopsy: are there similar sampling and diagnostic issues? *Clin Lab Med* 2005;25:679-88.
48. Goyal A, Douglas-Jones A, Monypenny I, Sweetland H, Stevens G, Mansel RE. Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 cases. *Breast Cancer Res Treat* 2006;98:311-4.
49. Sakr R, Barranger E, Antoine M, Prugnotte H, Darai E, Uzan S. Ductal carcinoma in situ: value of sentinel lymph node biopsy. *J Surg Oncol* 2006;94:426-30.

50. Yen TW, Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. *J Am Coll Surg* 2005;200:516-26.
51. Shin HJ, Sneige N. Is a diagnosis of infiltrating versus in situ ductal carcinoma of the breast possible in fine-needle aspiration specimens? *Cancer* 1998;84:186-191
52. McKee GT, Tambouret RH, Finkelstein D. Fine-needle aspiration cytology of the breast: Invasive vs. in situ carcinoma. *Diagn Cytopathol* 2001;25:73-7.
53. Provenzano E, Pinder SE. Pre-operative diagnosis of breast cancer in screening: problems and pitfalls. *Pathology* 2009;41:3-17.
54. Tan SM, Behranwala KA, Trott PA, et al. A retrospective study comparing the individual modalities of triple assessment in the pre-operative diagnosis of invasive lobular breast carcinoma. *Eur J Surg Oncol* 2002;28:203-8.
55. Moore MM, Borossa G, Imbrie JZ, et al. Association of infiltrating lobular carcinoma with positive surgical margins after breast-conservation therapy. *Ann Surg* 2000;231:877-82.
56. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. *Breast Cancer Res* 2004;6:R149-56.
57. Dillon MF, McDermott EW, Hill AD, O'Doherty A, O'Higgins N, Quinn CM. Predictive value of breast lesions of "uncertain malignant potential" and "suspicious for malignancy" determined by needle core biopsy. *Ann Surg Oncol* 2007;14:704-11.
58. Houssami N, Ciatto S, Ellis I, Ambrogetti D. Underestimation of malignancy of breast core-needle biopsy: concepts and precise overall and category-specific estimates. *Cancer* 2007;109:487-95.
59. Liu SV, Melstrom L, Yao K, Russell CA, Sener SF. Neoadjuvant therapy for breast cancer. *J Surg Oncol* 2010;101:283-91.
60. Rakha EA, Ellis IO. An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens. *J Clin Pathol* 2007;60:1300-6.

61. Bozzetti C, Nizzoli R, Guazzi A, et al. HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. *Ann Oncol* 2002;13:1398-1403.
62. Konofaos P, Kontzoglou K, Georgoulakis J, et al. The role of ThinPrep cytology in the evaluation of estrogen and progesterone receptor content of breast tumors. *Surg Oncol* 2006;15:257-66.
63. Andrade VP, Gobbi H. Accuracy of typing and grading invasive mammary carcinomas on core needle biopsy compared with the excisional specimen. *Virchows Arch* 2004;445:597-602.
64. Robinson IA, McKee G, Nicholson A, et al. Prognostic value of cytological grading of fine-needle aspirates from breast carcinomas. *Lancet* 1994;16:947-9.
65. Sriwatanakul K, Kelvie W, Lasagna L, Calimlim JF, Weis OF, Mehta G. Studies with different types of visual analog scales for measurement of pain. *Clin Pharmacol Ther* 1983;34:234-9.
66. Daltrey IR, Kissin MW. Randomized clinical trial of the effect of needle gauge and local anaesthetic on the pain of breast fine-needle aspiration cytology. *Br J Surg* 2000;87:777-9.
67. Zagouri F, Sergentanis TN, Gounaris A, et al. Pain in different methods of breast biopsy: emphasis on vacuum-assisted breast biopsy. *Breast* 2008;17:71-5.
68. Satchithananda K, Fernando RA, Ralleigh G, et al. An audit of pain/discomfort experienced during image-guided breast biopsy procedures. *Breast J* 2005;11:398-402.
69. Bates T, Davidson T, Mansel RE. Litigation for pneumothorax as a complication of fine-needle aspiration of the breast. *Br J Surg* 2002;89:134-7.
70. Meyer JE, Smith DN, Lester SC, et al. Large-core needle biopsy of nonpalpable breast lesions. *JAMA* 1999;281:1638-41.
71. Helvie MA, Ikeda DM, Adler DD. Localization and needle aspiration of breast lesions: complications in 370 cases. *AJR Am J Roentgenol* 1991;157:711-4.
72. Parker S, Burbank F, Jackman RJ, et al. Percutaneous large-core breast biopsy: a multi-institutional study. *Radiology* 1994;193:359-64.

73. He Q, Fan X, Yuan T, et al. Eleven years of experience reveals that fine-needle aspiration cytology is still a useful method for preoperative diagnosis of breast carcinoma. *Breast* 2007;16:303-306.
74. Lipshy KA, Neifeld JP, Boyle RM, et al. Complications of mastectomy and their relationship to biopsy technique. *Ann Surg Oncol* 1996;3:290-294.
75. Hoorntje LE, Schipper ME, Kaya A, Verkooijen HM, Klinkenbijnl JG, Borel Rinkes IH. Tumour cell displacement after 14G breast biopsy. *Eur J Surg Oncol* 2004;30:520-5.
76. Diaz LK, Wiley EL, Venta LA. Are malignant cells displaced by large-gauge needle core biopsy of the breast? *AJR Am J Roentgenol* 1999;173:1303-13.
77. Youngson BJ, Liberman L, Rosen PP. Displacement of carcinomatous epithelium in surgical breast specimens following stereotaxic core biopsy. *Am J Clin Pathol* 1995;103:598-602.
78. Hansen NM, Ye X, Grube BJ, Giuliano AE. Manipulation of the primary breast tumor and the incidence of sentinel node metastases from invasive breast cancer. *Arch Surg* 2004;139:634-40.
79. Fitzal F, Sporn EP, Draxler W, et al. Preoperative core needle biopsy does not increase local recurrence rate in breast cancer patients. *Breast Cancer Res Treat* 2006;97:9-15.
80. Green RS, Mathew S. The contribution of cytologic imprints of stereotactically guided core needle biopsies of the breast in the management of patients with mammographic abnormalities. *Breast J* 2001;7:214-8.
81. Klevesath MB, Godwin RJ, Bannon R, Munthali L, Coveney E. Touch imprint cytology of core needle biopsy specimens: a useful method for immediate reporting of symptomatic breast lesions. *Eur J Surg Oncol* 2005;31:490-4.
82. Fotou M, Oikonomou V, Zagouri F, et al. Imprint cytology on microcalcifications excised by vacuum-assisted breast biopsy: a rapid preliminary diagnosis. *World J Surg Oncol* 2007;5:40.
83. Oikonomou V, Fotou M, Zagouri F, et al. Imprint cytology of vacuum-assisted breast biopsy specimens: a rapid diagnostic tool in non-palpable solid lesions. *Cytopathol* 2008;19:311-5.
84. Kulkarni D, Irvine T, Reyes RJ. The use of core biopsy imprint cytology in the 'one-stop' breast clinic. *Eur J Surg Oncol* 2009;35:1037-40.

85. Wauters CA, Sanders-Eras CT, Kooistra BW, Strobbe LJ. Modified core wash cytology procedure for the immediate diagnosis of core needle biopsies of breast lesions. *Cancer Cytopathol* 2009;117:333-7.
86. Farshid , Pieterse S. Core imprint cytology of screen-detected breast lesions is predictive of the histologic results. *Cancer* 2006;108:150-6.
87. Jones L, Lott MF, Calder CJ, Kutt E. Imprint cytology from ultrasound-guided core biopsies: accurate and immediate diagnosis in a one-stop breast clinic. *Clin Radiol* 2004;59:903-8.
88. Kass R, Henry-Tillman RS, Nurko J, et al. Touch preparation of breast core needle specimens is a new method for same-day diagnosis. *Am J Surg* 2003;186:737-41.
89. Sneige N, Tulbah A. Accuracy of cytologic diagnoses made from touch imprints of image-guided needle biopsy specimens of nonpalpable breast abnormalities. *Diagn Cytopathol* 2000;23:29-34.
90. Lankford KV, Kluskens L, Dowlatshahi K, Reddy VB, Gattuso P. Utilization of core wash material in the diagnosis of breast lesions by stereotactic needle biopsy. *Cancer* 1998;84:98-100.
91. Uematsu T, Kasami M. Core wash cytology of breast lesions by ultrasonographically guided core needle biopsy. *Breast Cancer Res Treat* 2008;109:251-3.

**FIGURE CAPTION****Figure 1. Conclusiveness rates of FNA and CNB in prospective, directly comparative studies**

\*  $P < .05$

†  $P < .005$

‡  $P < .001$

Red dots delineate estimates of FNA conclusiveness, whereas blue dots delineate estimates of CNB conclusiveness. Horizontal lines correspond to 95% confidence intervals.

FNA indicates fine needle aspiration; CNB, core needle biopsy; 95% CI, 95% confidence interval.

## TABLES

Table 1. Definition of conclusive and inconclusive diagnoses by FNA and CNB

Preoperative diagnosis	Modality		Conclusive?	
	FNA	CNB	Benign follow-up <sup>a</sup>	Malignant follow-up <sup>a</sup>
Inadequate	C1	B1	No	No
Benign	C2	B2	Yes	No
Atypical	C3	B3	No	No
Suspicious	C4	B4	No	No
Malignant	C5	B5	No	Yes

<sup>a</sup> Either surgical or clinical/radiographic

**Table 2. Differences between FNA and CNB regarding their impact on the surgical management of breast lesions**

<b>Influence</b>	<b>FNA</b>	<b>CNB</b>
Same-day decision making and patient counselling	+	+/-
Preclude excision of benign lesions	+	+
Preclude excisional biopsy of malignant lesions	+	+
Differentiation of in situ vs. invasive carcinoma	-	+
Differentiation of lobular vs. ductal carcinoma	+/-	+
Accurate identification of high-risk lesions <sup>a</sup>	-	+
Complete lesion removal	-	+/-

<sup>a</sup> Such as atypical ductal hyperplasia, atypical papillomatosis, atypical lobular hyperplasia, lobular carcinoma in situ and flat epithelial atypia

FNA indicates fine needle aspiration; CNB, core needle biopsy


**Table 3. Overview of conclusiveness rates of preliminary diagnoses by touch imprint and core wash cytology**

Author [reference]	Modality	Design	N	Conclusiveness (%)		Concordance with CNB (%)
				Benign lesions	Malignant lesions	
Wauters 2009[91]	TI	Prospective	30	67	75	70
Kulkarni 2009[90]	TI	Retrospective	813	84	87	96
Oikonomou 2008[89]	TI	Retrospective	72	93	90	90
Foutou 2007[88]	TI	Retrospective	93	85	100	-
Fashid 2006[92]	TI	Retrospective	567	56	42	47
Klevesath 2005[87]	TI	Retrospective	128	63	85	91
Jones 2004[93]	TI	Prospective	111	76	81	80
Kass 2003[94]	TI	Retrospective	199	62	58	62
Green 2001[86]	TI	Retrospective	100	-	-	84
Sneige 2000[95]	TI	Retrospective	172	44	62	58
Wauters 2009[91]	CW	Prospective	30	89	75	73
Uematsu	CW	Prospective	458	32	38	33

2008[97]						
Lankford	CW					
1998[96]		Retrospective	211	85	39	83

CNB indicates core needle biopsy; TI, touch imprint cytology; CW, core wash cytology

Empty cells indicate that calculation of the respective parameter was impossible because of insufficient data presentation in the published paper



ACCEPTED MANUSCRIPT